Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer July 14, 2022July 14, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: [Ad hoc announcement pursuant to Art. 53 LR] Roche’s…Roche's Kadcyla is the first targeted therapy…Roche’s inavolisib combination reduces the risk of…Early treatment with Roche's OCREVUS leads to…New phase III data show Roche’s Vabysmo rapidly…Do You Want To Reduce Risk After Retirement? Know…
